RSLV-132 is a novel RNase-Fc fusion protein designed to remove RNA, a pro-inflammatory nucleic acid which accumulates in the blood of patients with autoimmune diseases such as lupus and Sjögren’s syndrome. Resolve has completed a positive P2a clinical trial in lupus and expects to initiate pivotal registration studies in Sjögren’s syndrome in 2022.

Cropped Diseases.jpg

RSLV-132 in Lupus and Sjögren’s syndrome

Lupus and Sjögren’s syndrome are systemic autoimmune diseases that primarily affect women and occur when the immune system attacks its own body. For lupus, the standard of care has not significantly improved in over 40 years and current treatment options have limited efficacy and serious side effects. There are currently no approved therapies for Sjögren’s syndrome and most treatments focus on temporarily relieving dry eyes and mouth. The defining characteristic of both lupus and Sjögren’s are RNA-containing autoantigens which are maintained in circulation by autoantibodies. RSLV-132 degrades this RNA, thereby preventing ongoing inflammation and associated organ damage.